Field Trip Health Ltd. Applies to List Its Common Shares on the NASDAQ Stock Market
After a successful listing on the TSX, Field Trip Health Ltd. applied to list on the NASDAQ Stock Exchange, which would allow US investors to support their growth. Field Trip executives state that this move declares to the public that they are a world class company, and that they are “positioned to be the global leader in the psychedelics industry”. Field Trip expects to commence with Phase 1 human trials of their proprietary psychedelic molecule by the end of 2021, and will have 20 health centers operating or under construction across the US, Canada, and Europe.